SCPH
Price
$3.94
Change
-$0.00 (-0.00%)
Updated
Oct 9 closing price
27 days until earnings call
XERS
Price
$2.81
Change
-$0.00 (-0.00%)
Updated
Oct 9 closing price
28 days until earnings call
Ad is loading...

SCPH vs XERS

Header iconSCPH vs XERS Comparison
Open Charts SCPH vs XERSBanner chart's image
scPharmaceuticals
Price$3.94
Change-$0.00 (-0.00%)
Volume$263.34K
CapitalizationN/A
Xeris Biopharma Holdings
Price$2.81
Change-$0.00 (-0.00%)
Volume$1.5M
CapitalizationN/A
View a ticker or compare two or three
SCPH vs XERS Comparison Chart
Loading...
SCPH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
SCPH vs. XERS commentary
Oct 11, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCPH is a Hold and XERS is a Hold.

COMPARISON
Comparison
Oct 11, 2024
Stock price -- (SCPH: $3.94 vs. XERS: $2.81)
Brand notoriety: SCPH and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SCPH: 77% vs. XERS: 90%
Market capitalization -- SCPH: $228.63M vs. XERS: $427.63M
SCPH [@Biotechnology] is valued at $228.63M. XERS’s [@Biotechnology] market capitalization is $427.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCPH’s FA Score shows that 0 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • SCPH’s FA Score: 0 green, 5 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, XERS is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCPH’s TA Score shows that 5 TA indicator(s) are bullish while XERS’s TA Score has 3 bullish TA indicator(s).

  • SCPH’s TA Score: 5 bullish, 5 bearish.
  • XERS’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both SCPH and XERS are a good buy in the short-term.

Price Growth

SCPH (@Biotechnology) experienced а -9.63% price change this week, while XERS (@Biotechnology) price change was -3.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

SCPH is expected to report earnings on Mar 19, 2025.

XERS is expected to report earnings on Mar 05, 2025.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XERS($428M) has a higher market cap than SCPH($229M). XERS YTD gains are higher at: 19.574 vs. SCPH (-37.161). XERS has higher annual earnings (EBITDA): -17.24M vs. SCPH (-51.74M). XERS has more cash in the bank: 77.6M vs. SCPH (38.5M). SCPH has less debt than XERS: SCPH (41.4M) vs XERS (270M). XERS has higher revenues than SCPH: XERS (181M) vs SCPH (24M).
SCPHXERSSCPH / XERS
Capitalization229M428M54%
EBITDA-51.74M-17.24M300%
Gain YTD-37.16119.574-190%
P/E RatioN/AN/A-
Revenue24M181M13%
Total Cash38.5M77.6M50%
Total Debt41.4M270M15%
FUNDAMENTALS RATINGS
SCPH vs XERS: Fundamental Ratings
SCPH
XERS
OUTLOOK RATING
1..100
5384
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8537
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (81) in the Pharmaceuticals Major industry is in the same range as XERS (92). This means that SCPH’s stock grew similarly to XERS’s over the last 12 months.

SCPH's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as XERS (100). This means that SCPH’s stock grew similarly to XERS’s over the last 12 months.

SCPH's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as XERS (100). This means that SCPH’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for SCPH (85). This means that XERS’s stock grew somewhat faster than SCPH’s over the last 12 months.

XERS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as SCPH (100). This means that XERS’s stock grew similarly to SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCPHXERS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 25 days ago
79%
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
SCPH
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL229.543.77
+1.67%
Apple
SPY577.143.97
+0.69%
SPDR® S&P 500® ETF Trust
GME20.50-0.21
-1.01%
GameStop Corp
TSLA241.05-3.45
-1.41%
Tesla
BTC.X60582.100000-1549.867200
-2.49%
Bitcoin cryptocurrency

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with INZY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-0.88%
INZY - SCPH
44%
Loosely correlated
-2.67%
XERS - SCPH
44%
Loosely correlated
-4.42%
BEAM - SCPH
43%
Loosely correlated
+0.77%
MGTX - SCPH
43%
Loosely correlated
+0.24%
NTLA - SCPH
43%
Loosely correlated
-1.34%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with LXRX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then LXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-4.42%
LXRX - XERS
44%
Loosely correlated
-2.98%
SCPH - XERS
43%
Loosely correlated
-0.88%
NTLA - XERS
42%
Loosely correlated
-1.34%
INZY - XERS
40%
Loosely correlated
-2.67%
RXRX - XERS
40%
Loosely correlated
-4.50%
More